Transarterial‐ chemoembolization remains an effective therapy for intermediate‐stage hepatocellular carcinoma with preserved liver function

Autor:	Hiroshi Sakaguchi, Takeshi Sato, Nagaaki Marugami, Natsuhiko Saito, Toshihiro Tanaka, Satoru Sueyoshi, Kimihiko Kichikawa, Hideyuki Nishiohuku, Takeshi Matsumoto, Hiroshi Anai, Tetsuya Masada
Rok vydání:	2020
Předmět:	medicine.medical_specialty Poor prognosis Hepatology business.industry Proportional hazards model Tumor response medicine.disease Gastroenterology Intermediate stage 03 medical and health sciences 0302 clinical medicine Infectious Diseases 030220 oncology & carcinogenesis Internal medicine Hepatocellular carcinoma Medicine Combined therapy 030211 gastroenterology & hepatology Liver function business Median survival
Zdroj:	Hepatology Research. 50:1176-1185
ISSN:	1872-034X 1386-6346
DOI:	10.1111/hepr.13550
Popis:	Aim To evaluate outcomes as well as prognostic factors of transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma (HCC) with preserved liver function to determine positioning of TACE. Methods Of 158 treatment-naive patients with intermediate-stage HCC who received initial TACE from February 2007 to January 2016, 113 patients met the following inclusion criteria: no combined therapy within 4 weeks after initial TACE, and Child-Pugh score under 7. Response rate and overall survival were evaluated. The prognostic factors were investigated in univariate and multivariate analyses using Cox proportional hazards models. The deterioration of liver function after repeated TACE was also evaluated. Results The response rate was 92.7% (complete response, 63.3%; partial response, 29.4%). The median survival time was 45.2 months. Survival rates at 1, 2, and 3 years were 90.4%, 77.0%, and 60.8% respectively. Age ≥ 75 years (P = 0.022), serum α-fetoprotein level ≥ 200 ng/mL (P = .010), tumor number ≥ 11 (P = 0.008), and heterogeneous enhancement on dynamic computed tomography (P = 0.024) were poor prognostic factors. The deterioration rate of Child-Pugh score and albumin-bilirubin grade was 18.5% and 12.3%, respectively, after the first TACE, 15.6% and 5.1%, respectively, after the second TACE, and 14.5% and 11.1%, respectively, after the third TACE. Conclusion Superselective TACE can achieve high tumor response rates with prolonged overall survival for patients with intermediate-stage HCC with preserved liver function. Age, serum α-fetoprotein level, tumor number ≥ 11, and heterogeneous enhancement on dynamic computed tomography indicated significantly poor prognosis.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21df8809d4b49367b1b00bac8bc9c19b https://doi.org/10.1111/hepr.13550 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.